Literature DB >> 8406872

Humoral immune response to the class 3 outer membrane protein during the course of meningococcal disease.

H K Guttormsen1, L M Wetzler, A Naess.   

Abstract

We have determined the amounts of specific anti-class 3 outer membrane protein antibodies of immunoglobulin G (IgG), IgM, and IgA isotypes in patient sera during the course of meningococcal disease by using purified class 3 protein as the sensitizing antigen in an enzyme-linked immunosorbent assay. The class 3 protein was obtained from a variant of strain 44/76 (B:15:P1.7,16) lacking class 1 and class 4 outer membrane proteins. Serum samples from 25 patients with systemic meningococcal disease caused by organisms of various serotypes were collected during the course of disease. Seven of these patients had been immunized with a meningococcal outer membrane vesicle vaccine made from strain 44/76 prior to disease. An increase in specific anti-class 3 (type 15) outer membrane protein IgG antibodies was demonstrated in 22 of 25 patients (88%), regardless of the serotype of the infecting strain. This indicates that the specific anti-class 3 antibodies were reacting in part with epitopes not determined by the monoclonal antibodies used for serotyping. A considerable heterogeneity in antibody levels and IgG subclass response was seen. Most patients had low levels of anti-class 3 antibodies during the acute illness, with antibodies peaking during the second week of disease and returning to near baseline in sera collected 6 to 12 months after the onset of the disease. The majority of the specific anti-class 3 IgG antibodies were shown to bind to surface-exposed epitopes on the whole bacteria and to belong to IgG1 and IgG3. The highest anti-class 3 IgG peak levels were seen in patients infected with strains of the homologous serotype after vaccination with the meningococcal outer membrane vesicle vaccine, suggesting an anamnestic response. However, these patients were not protected from meningococcal disease after immunization.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8406872      PMCID: PMC281228          DOI: 10.1128/iai.61.11.4734-4742.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  The lipooligosaccharide immunotype as a virulence determinant in Neisseria meningitidis.

Authors:  D M Jones; R Borrow; A J Fox; S Gray; K A Cartwright; J T Poolman
Journal:  Microb Pathog       Date:  1992-09       Impact factor: 3.738

2.  Gonococcal porin vaccine evaluation: comparison of Por proteosomes, liposomes, and blebs isolated from rmp deletion mutants.

Authors:  L M Wetzler; M S Blake; K Barry; E C Gotschlich
Journal:  J Infect Dis       Date:  1992-09       Impact factor: 5.226

3.  Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway.

Authors:  G Bjune; E A Høiby; J K Grønnesby; O Arnesen; J H Fredriksen; A Halstensen; E Holten; A K Lindbak; H Nøkleby; E Rosenqvist
Journal:  Lancet       Date:  1991-11-02       Impact factor: 79.321

4.  Isolation of Neisseria meningitidis mutants deficient in class 1 (porA) and class 3 (porB) outer membrane proteins.

Authors:  J Tommassen; P Vermeij; M Struyvé; R Benz; J T Poolman
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

5.  Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes.

Authors:  E Engvall; P Perlmann
Journal:  J Immunol       Date:  1972-07       Impact factor: 5.422

6.  Immunologic response of man to group B meningococcal polysaccharide vaccines.

Authors:  F A Wyle; M S Artenstein; B L Brandt; E C Tramont; D L Kasper; P L Altieri; S L Berman; J P Lowenthal
Journal:  J Infect Dis       Date:  1972-11       Impact factor: 5.226

7.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

8.  Cross-reacting serum opsonins in patients with meningococcal disease.

Authors:  H K Guttormsen; R Bjerknes; A Naess; V Lehmann; A Halstensen; S Sørnes; C O Solberg
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

9.  IgG subclass antibodies to serogroup B meningococcal outer membrane antigens following infection and vaccination.

Authors:  H Sjursen; E Wedege; E Rosenqvist; A Naess; A Halstensen; R Matre; C O Solberg
Journal:  APMIS       Date:  1990-12       Impact factor: 3.205

10.  Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay.

Authors:  K Saukkonen; M Leinonen; H Abdillahi; J T Poolman
Journal:  Vaccine       Date:  1989-08       Impact factor: 3.641

View more
  22 in total

1.  Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB.

Authors:  A K Lehmann; A Halstensen; I S Aaberge; J Holst; T E Michaelsen; S Sornes; L M Wetzler; H Guttormsen
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  DNA Sequence analysis of the PorB protein of nonserotypeable serogroup C ET-15 meningococci suggests a potential mutational hot spot on their serotype antigens.

Authors:  Dennis K S Law; Averil M Henderson; Raymond S W Tsang
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

3.  Neisseria meningitidis lipopolysaccharide modulates the specific humoral immune response to neisserial porins but has no effect on porin-induced upregulation of costimulatory ligand B7-2.

Authors:  N Bhasin; Y Ho; L M Wetzler
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

4.  Immunoproteomic analysis of the development of natural immunity in subjects colonized by Neisseria meningitidis reveals potential vaccine candidates.

Authors:  Jeannette N Williams; Paul J Skipp; C David O'Connor; Myron Christodoulides; John E Heckels
Journal:  Infect Immun       Date:  2009-09-08       Impact factor: 3.441

5.  Analysis of antigenic structure and human immune response to outer membrane protein CD of Moraxella catarrhalis.

Authors:  T F Murphy; C Kirkham; E DeNardin; S Sethi
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

6.  Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial.

Authors:  E Wedege; E A Høiby; E Rosenqvist; G Bjune
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

7.  Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine.

Authors:  L G Milagres; M C Gorla; C T Sacchi; M M Rodrigues
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

8.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.

Authors:  E Rosenqvist; E A Høiby; E Wedege; K Bryn; J Kolberg; A Klem; E Rønnild; G Bjune; H Nøkleby
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

9.  Neisserial porins inhibit human neutrophil actin polymerization, degranulation, opsonin receptor expression, and phagocytosis but prime the neutrophils to increase their oxidative burst.

Authors:  R Bjerknes; H K Guttormsen; C O Solberg; L M Wetzler
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

10.  Role of protein tyrosine kinase and Erk1/2 activities in the Toll-like receptor 2-induced cellular activation of murine B cells by neisserial porin.

Authors:  Heather MacLeod; Navneet Bhasin; Lee M Wetzler
Journal:  Clin Vaccine Immunol       Date:  2008-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.